



Plan for revisiting the adolescent schedule for meningococcal vaccines

Lucy McNamara, PhD, MS

Interim Co-Lead, ACIP Meningococcal Vaccines Work Group

October 25, 2023

Considerations for routine schedule discussed during June 2023 ACIP meeting

- Strong interest in revisiting the meningococcal vaccine schedule, including
 - Whether 11–12-year old dose is still needed given recent epidemiology
 - Revisiting SCDM for B vaccines
 - Pentavalent vaccines may complicate the SCDM discussion for providers
 - Nuances such as short duration of B protection may be lost in favor of giving a single injection
- Opportunity to reduce number of vaccines (i.e., with pentavalent vaccines) is appealing if maintaining a high level of protection

The Meningococcal Vaccines WG plans to revisit the schedule over the next year to ensure

- Adequate time to perform GRADE and EtR assessments
- Assessment of extended interval data for pentavalent vaccines
- Integration of any changes into the overall child and adolescent immunization schedule
- Assessment of post-COVID epidemiology

Proposed key questions

- Should the MenACWY series recommendations be changed to
 - Begin at an older age than currently recommended (11–12 years)
 - Eliminate the 11–12 year-old dose or change this recommendation to SCDM?
- Should the MenB series recommendations be changed to
 - Alter the recommended ages or dosing interval to provide better protection for individuals aged 18–19 years?
 - Revisit the SCDM recommendation for some or all adolescents (e.g., those planning to attend college)?
- Are there ways we can better integrate MenACWY and MenB vaccine schedules to streamline administration/increase feasibility?

Tentative timeline for ACIP meetings, 2024–2025

Date	Topics
Feb 2024	- Terms of reference for schedule change
June 2024	- Epidemiology pertinent to possible schedule changes <ul style="list-style-type: none">· Cases/deaths averted by MenACWY dose at 11–12y· Meningococcal disease burden stratified by race/ethnicity in adolescents· Risk factors for serogroup B meningococcal disease among college vs. non-college students· Breakthrough meningococcal disease cases in vaccinated individuals· Extended interval data for pentavalent vaccines
Oct 2024	- GRADE/EtR for changes to MenACWY and MenB adolescent schedules - CE analysis for changes to MenACWY and MenB adolescent schedules
Feb 2025	- Votes

Acknowledgments

- ACIP Members on the WG
 - Kathy Poehling (Chair)
 - Lynn Bahta
 - Jamie Loehr
- Ex Officio WG Members
 - Margaret Bash (FDA)
 - Mark Connelly (FDA)
 - Francisco Leyva (NIH)
- WG Liaisons and Consultants
 - Amra Resic (AAFP)
 - Samir Shah (AAP)
 - Sharon McMullen (ACHA)
 - Cacky Tate / Karyn Lyons (AIM)
 - Paul Cieslak (CSTE)
 - Kathy Hsu (IDSA)
 - Joseline Zafack (NACI)
 - Jeff Goad (NFID)
 - Jessica Cataldi (PIDS)
 - Amy Middleman (SAHM)
 - David Stephens (Emory)
- CDC Contributors
 - Jennifer Collins (DBD/NCIRD)
 - Sam Crowe (DBD/NCIRD)
 - Ismael Ortega-Sanchez (DVD/NCIRD)
 - Andrew Leidner (ISD/NCIRD)
 - LeAnne Fox (DBD/NCIRD)
 - Susan Hariri (DBD/NCIRD)
 - Amy Rubis (DBD/NCIRD)
 - Noele Nelson (DBD/NCIRD)
 - Alison Albert (DBD/NCIRD)
 - Angela Jiles (DBD/NCIRD)
 - Jonathan Duffy (DHQP/NCEZID)
 - Tanya Myers (DHQP/NCEZID)
 - Liz Velazquez (ISD/NCIRD)
 - Jessica MacNeil (ACIP Secretariat)
 - Melinda Wharton (ACIP Secretariat)
- GRADE/EtR Support
 - Doug Campos-Outcalt (Arizona)
 - Rebecca Morgan (Case Western Reserve)

Thank you!
Questions?